PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The programmed death-ligand 1 (PD-L1) SP142 assay identifies patients with triple-negative breast cancer (TNBC) who are most likely to respond to the anti–PD-L1 agent atezolizumab. We aimed to compare PD-L1 (SP142) expression between primary and recurrent/metastatic TNBCs and elucidate the clinicopathological features associated with its expression. Materials and Methods Primary and recurrent/metastatic TNBCs tested with PD-L1 (SP142) were collected, and clinicopathological information of these cases was obtained through a review of slides and medical records. Results PD-L1 (SP142) positivity was observed in 50.9% (144/283) of primary tumors and 37.8% (31/82) of recurrent/metastatic TNBCs with a significant difference. Recurrent or metastatic sites were associated with PD-L1 positivity, with high PD-L1 positivity in the lung, breast, and soft tissues, and low positivity in the bone, skin, liver, and brain. When comparing PD-L1 expression between primary and matched recurrent/metastatic TNBCs using 55 paired samples, 20 cases (36.4%) showed discordance; 10 cases revealed positive conversion, and another 10 cases revealed negative conversion during metastatic progression. In primary TNBCs, PD-L1 expression was associated with a higher histologic grade, lower T category, pushing border, and higher tumor-infiltrating lymphocyte infiltration. In survival analyses, PD-L1 positivity, especially high positivity, was found to be associated with favorable prognosis of patients. Conclusion PD-L1 (SP142) expression was lower in recurrent/metastatic TNBCs, and substantial cases showed discordance in its expression between primary and recurrent/metastatic sites, suggesting that multiple sites may need to be tested for PD-L1 (SP142) when considering atezolizumab therapy. PD-L1 (SP142)–positive TNBCs seems to be associated with favorable clinical outcomes.
Abstract
Purpose The programmed death-ligand 1 (PD-L1) SP142 assay identifies patients with triple-negative breast cancer (TNBC) who are most likely to respond to the anti–PD-L1 agent atezolizumab. We aimed to compare PD-L1 (SP142) expression between primary and recurrent/metastatic TNBCs and elucidate the clinicopathological features associated with its expression. Materials and Methods Primary and recurrent/metastatic TNBCs tested with PD-L1 (SP142) were collected, and clinicopathological information of these cases was obtained through a review of slides and medical records. Results PD-L1 (SP142) positivity was observed in 50.9% (144/283) of primary tumors and 37.8% (31/82) of recurrent/metastatic TNBCs with a significant difference. Recurrent or metastatic sites were associated with PD-L1 positivity, with high PD-L1 positivity in the lung, breast, and soft tissues, and low positivity in the bone, skin, liver, and brain. When comparing PD-L1 expression between primary and matched recurrent/metastatic TNBCs using 55 paired samples, 20 cases (36.4%) showed discordance; 10 cases revealed positive conversion, and another 10 cases revealed negative conversion during metastatic progression. In primary TNBCs, PD-L1 expression was associated with a higher histologic grade, lower T category, pushing border, and higher tumor-infiltrating lymphocyte infiltration. In survival analyses, PD-L1 positivity, especially high positivity, was found to be associated with favorable prognosis of patients. Conclusion PD-L1 (SP142) expression was lower in recurrent/metastatic TNBCs, and substantial cases showed discordance in its expression between primary and recurrent/metastatic sites, suggesting that multiple sites may need to be tested for PD-L1 (SP142) when considering atezolizumab therapy. PD-L1 (SP142)–positive TNBCs seems to be associated with favorable clinical outcomes.
참고문헌 (30)
- Sorlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", Proc Natl Acad Sci U S A, 98, pp.10869~10874 (2001)
- Robson M, "Olaparib for metastatic breast cancer in patients with a germline BRCA mutation", N Engl J Med, 377, pp.523~533 (2017)
- Litton JK, "Talazoparib in patients with advanced breast cancer and a germline BRCA mutation", N Engl J Med, 379, pp.753~763 (2018)
- Lawrence MS, "Mutational heterogeneity in cancer and the search for new cancer-associated genes", Nature, 499, pp.214~218 (2013)
- Luen S, "The genomic landscape of breast cancer and its interaction with host immu-nity", Breast, 29, pp.241~250 (2016)
- Mittendorf EA, "PD-L1 expression in triple-negative breast cancer", Cancer Immunol Res, 2, pp.361~370 (2014)
- Loi S, "Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy : BIG 02-98", J Clin Oncol, 31, pp.860~867 (2013)
- Tan Q, "Potential predictive and prognostic value of biomarkers related to immune checkpoint inhibitor therapy of triple-negative breast cancer", Front Oncol, 12, pp.779786~ (2022)
- Freeman GJ, "Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation", J Exp Med, 192, pp.1027~1034 (2000)
- Ribas A, "Tumor immunotherapy directed at PD-1", N Engl J Med, 366, pp.2517~2519 (2012)
- Cortes J, "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer(KEYNOTE-355) : a randomised, placebo-controlled, double-blind, phase 3 clinical trial", Lancet, 396, pp.1817~1828 (2020)
- Schmid P, "Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer", N Engl J Med, 379, pp.2108~2121 (2018)
- Hoda RS, "Clinical and pathologic features associated with PD-L1(SP142)expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma", Mod Pathol, 33, pp.2221~2232 (2020)
- Rozenblit M, "Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers", J Immunother Cancer, 8, pp.e001558~ (2020)
- Manson QF, "Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases", Clin Exp Metastasis, 36, pp.29~37 (2019)
- Tawfik O, "Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells", Hum Pathol, 80, pp.170~178 (2018)
- Li Y, "Prevalence study of PD-L1 SP142 assay in metastatic triple-negative breast cancer", Appl Immunohistochem Mol Morphol, 29, pp.258~264 (2021)
- Miyakoshi J, "Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer", Virchows Arch, 483, pp.855~863 (2023)
- Ogiya R, "Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients", Cancer Sci, 107, pp.1730~1735 (2016)
- Cimino-Mathews A, "Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors : a pilot study", Hum Pathol, 44, pp.2055~2063 (2013)
- Sobottka B, "Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases", Oncoimmunology, 5, pp.e1153208~ (2016)
- Baek SH, "SP142 PD-L1 assays in multiple samples from the same patients with early or advanced triple-negative breast cancer", Cancers(Basel), 14, pp.3042~ (2022)
- Dieci MV, "Immune characterization of breast cancer metastases : prognostic implications", Breast Cancer Res, 20, pp.62~ (2018)
- Boman C, "Discordance of PD-L1 status between primary and metastatic breast cancer : a systematic review and meta-analysis", Cancer Treat Rev, 99, pp.102257~ (2021)
- Peg V, "PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer : summary of an expert round-table discussion", Future Oncol, 17, pp.1209~1218 (2021)
- Ghosh J, "PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer(TNBC)", Ecancermedicalscience, 15, pp.1217~ (2021)
- Wang X, "PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer", Pathol Res Pract, 216, pp.152802~ (2020)
- Beckers RK, "Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome", Histopathology, 69, pp.25~34 (2016)
- Denkert C, "Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer : a pooled analysis of 3771 patients treated with neoadjuvant therapy", Lancet Oncol, 19, pp.40~50 (2018)
- Gao G, "Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer : a systematic review and meta-analysis", BMC Cancer, 20, pp.179~ (2020)